 SAN DIEGO, Aug. 23, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento today released a patient case report on the lymphatic delivery of Enbrel using the Sofusa Lymphatic Delivery System SOFUSA, which has been submitted for preprint as CASE REPORT: Lymphatic delivery of Enbrel using The Sofusa Lymphatic Delivery System SOFUSA achieves improvement in rheumatoid arthritis disease activity measures in a patient non-responsive to Enbrel subcutaneous injections 